{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:58:59Z","timestamp":1790611139853,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03724-y","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:57:08Z","timestamp":1784537828000},"page":"4701-4717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Patient-Reported Outcomes for HTA Success: Lessons from German Early Benefit Assessments"],"prefix":"10.1007","volume":"43","author":[{"given":"Kristi A.","family":"Bertzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Alt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke K.","family":"Kummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Thiemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Frosien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"3724_CR1","unstructured":"HTA Coordination Group. Guidance on outcomes for joint clinical assessments. Adopted 10 June 2024. Directorate-General for Health and Food Safety, European Commission; 2024. https:\/\/health.ec.europa.eu\/document\/download\/a70a62c7-325c-401e-ba42-66174b656ab8_en?filename=hta_outcomes_jca_guidance_en.pdf. Accessed Feb 22, 2026."},{"key":"3724_CR2","unstructured":"Food and Drug Administration. Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring (MD): US Department of Health and Human Services; 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed Feb 22, 2026."},{"key":"3724_CR3","unstructured":"European Medicines Agency (EMA). Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man\u2014the use of patient-reported outcome (PRO) measures in oncology studies. EMA\/CHMP\/292464\/2014. London (UK): EMA; 2016. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed Feb 22, 2026."},{"issue":"Suppl 2","key":"3724_CR4","first-page":"S310","volume":"27","author":"G Sarri","year":"2024","unstructured":"Sarri G, Cala ML, Freitag A, Gurskyte L. Patient experience in health technology assessment (HTA): landscape assessment and comparison of HTA guidance on patient-reported outcomes. Value Health. 2024;27(Suppl 2):S310\u201320.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"3724_CR5","first-page":"S120","volume":"27","author":"M Chalmers","year":"2024","unstructured":"Chalmers M, Dunne R, Kanade P. Assessment of patient-reported outcomes in health technology assessment submissions across the UK, Germany, France, Italy, and Spain. Value Health. 2024;27(Suppl 1):S120\u20139.","journal-title":"Value Health"},{"key":"3724_CR6","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Benefit assessment of medicinal products in accordance with the German Social Code, Book Five (SGB V), section 35a. Berlin: G-BA; 2025. https:\/\/www.g-ba.de\/english\/benefitassessment\/. Accessed Feb 22, 2026."},{"key":"3724_CR7","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). General methods. Version 8.0. Cologne (DE): IQWiG; 2025. https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_v8-0.pdf. Accessed Feb 22, 2026."},{"issue":"Suppl 1","key":"3724_CR8","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jval.2018.09.397","volume":"21","author":"X Lie","year":"2018","unstructured":"Lie X, Kempf L, van Engen A. Impact of PRO data on IQWiG benefit ratings in oncology. Value Health. 2018;21(Suppl 1):S67\u20138. https:\/\/doi.org\/10.1016\/j.jval.2018.09.397.","journal-title":"Value Health"},{"issue":"2","key":"3724_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.18553\/jmcp.2017.23.2.125","volume":"23","author":"AP Brogan","year":"2017","unstructured":"Brogan AP, DeMuro C, Barrett AM, D\u2019Alessio D, Bal V, Hogue SL. Payer perspectives on patient-reported outcomes in health care decision-making: oncology examples. J Manag Care Spec Pharm. 2017;23(2):125\u201334. https:\/\/doi.org\/10.18553\/jmcp.2017.23.2.125.","journal-title":"J Manag Care Spec Pharm"},{"key":"3724_CR10","volume-title":"Patient-reported indicator surveys (PaRIS)","author":"Organization for Economic Co-operation and Development (OECD)","year":"2025","unstructured":"Organization for Economic Co-operation and Development (OECD). Patient-reported indicator surveys (PaRIS). Paris: OECD; 2025."},{"key":"3724_CR11","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Nutzenbewertung. G-BA. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/."},{"key":"3724_CR12","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Projects and results. IQWiG. https:\/\/www.iqwig.de\/en\/projects\/projects-results\/. Accessed Mar 5, 2026."},{"key":"3724_CR13","unstructured":"NAVLIN Price & Access Data. https:\/\/www.navlin.com\/products\/navlin-price-access-data. Accessed Mar 5, 2026."},{"key":"3724_CR14","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Selinexor (multiple myeloma; after at least one prior therapy, in combination with bortezomib and dexamethasone). Decision of 16 March 2023. Berlin: G-BA; 2023. https:\/\/www.g-ba.de\/beschluesse\/5903\/. Accessed Mar 10, 2026."},{"key":"3724_CR15","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Trastuzumab deruxtecan (new therapeutic indication: breast cancer, HER2-positive, after 1 prior therapy). Resolution of 2 February 2023. Berlin: G-BA; 2023. https:\/\/www.g-ba.de\/beschluesse\/5859\/. Accessed Mar 10, 2026."},{"key":"3724_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114313.9","volume":"212","author":"L van der Weijst","year":"2024","unstructured":"van der Weijst L, Kieffer JM, Snyder CF, et al. Improving completion rates of patient-reported outcome measures in oncology clinical trials: a review of EORTC trials. Eur J Cancer. 2024;212:114313. https:\/\/doi.org\/10.1016\/j.ejca.2024.114313.9.","journal-title":"Eur J Cancer"},{"key":"3724_CR17","unstructured":"Pushkarna D, del Aguila M, Collet JP, Fazeli MS. Role of PROs in HTA decision making across UK, Germany, France, Italy, and Spain (EU4+UK). Poster presented at: ISPOR Europe; 2025; Glasgow, UK. https:\/\/www.ispor.org\/docs\/default-source\/cti-meeting-21305-documents\/e00e8a13-7ee9-45e5-ad84-1b0692e7628c.pdf. Accessed Mar 05, 2026."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03724-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03724-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03724-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:37Z","timestamp":1790609977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03724-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3724"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03724-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kristi Bertzos, Nicole Alt, Peter Coyle, Katharine Gries, Anke Kummer, Anna Lieb, Sophie Thiemann, Daniel Wirth, and Markus Frosien are employees of Johnson & Johnson and may hold stock in the company. Shivani Shah is an employee of Eversana, which received funds from Johnson & Johnson to conduct the research described in this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized only publicly available data and did not involve human subjects or patient-level information. Therefore, ethics committee approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}